Significant ETF Withdrawals: ITOT, TSLA, PLTR, TMO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: NASDAQ.COM
52-Week Range of ITOT: ITOT's share price has a 52-week low of $105 and a high of $150.70, with the last trade recorded at $150.23.
Understanding ETFs: Exchange traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.
Monitoring ETF Flows: Weekly monitoring of shares outstanding helps identify ETFs with significant inflows (new units created) or outflows (units destroyed), impacting the underlying holdings.
Author's Views: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 513.330
Low
580.00
Averages
658.89
High
750.00
Current: 513.330
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offer virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcturus Partners with Thermo Fisher to Advance Cystic Fibrosis Therapy
- Partnership Agreement: Arcturus Therapeutics has signed a partnership with Thermo Fisher Scientific to advance ARCT-032, a therapy targeting cystic fibrosis, marking a strategic move in the rare disease treatment landscape.
- Clinical Research Support: Under the agreement, Thermo Fisher will provide its PPD clinical research services to assist Arcturus in conducting a Phase 3 trial for ARCT-032, contingent on positive Phase 2 data, paving the way for future market access.
- Commercial Agreement Established: Arcturus has also entered into a commercial agreement with Thermo Fisher, granting the latter exclusive rights to ARCT-032 pending regulatory approval, enhancing the depth of collaboration in the biopharmaceutical sector.
- Clinical Trial Progress: Currently, ARCT-032 is undergoing mid-stage development, with Arcturus awaiting 12-week data from a Phase 2 open-label trial, which will significantly impact its future market potential.
See More
Danaher Corporation Rated as Top Non-Tech Stock by Analysts
- FDA 510(k) Clearance: Masimo announced FDA 510(k) clearance for its Radius VSM® wearable continuous patient monitor, which now includes an opioid-induced respiratory depression detection capability that utilizes advanced pattern recognition to analyze continuous physiological data, enabling clinicians to identify early signs of respiratory compromise in patients receiving opioid therapy, thereby enhancing patient safety and monitoring efficiency.
- Analyst Rating Changes: Piper Sandler has initiated coverage of Danaher Corporation (DHR) while expressing caution regarding its future growth catalysts, noting that the current growth outlook is similar to past performance and that Thermo Fisher appears slightly cheaper on a P/E basis, indicating market divergence in expectations for Danaher's future performance.
- Market Positioning Analysis: Danaher’s design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services position it as a significant diagnostics stock, although analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse perspective on investment opportunities in the current market.
- Investment Potential Assessment: While Danaher is viewed as a potentially strong investment, analysts express insufficient confidence in its future growth, suggesting that in the current market environment, some AI stocks may be more attractive, prompting investors to carefully consider the balance of risk and reward in their selections.
See More
Thermo Fisher Named Among Top Dividend Stock Picks by Steven Cohen
- Dividend Stock Recommendation: Billionaire Steven Cohen includes Thermo Fisher Scientific (TMO) in his top 11 dividend stock picks, indicating strong recognition of the company's stable returns, which may attract more income-seeking investors.
- Analyst Coverage Resumed: Bernstein resumed coverage of TMO on June 26 with a Market Perform rating and a $520 price target, reflecting analysts' optimism about the life sciences tools and diagnostics sector, anticipating increased customer spending in the future.
- Industry Outlook Improvement: Bernstein noted improvements in new drug approvals, clinical trial initiations, and funding over the past 12 months, expecting these factors to drive customer spending growth, thereby enhancing Thermo Fisher's market performance.
- Market Competition Analysis: While Piper Sandler assigned a Neutral rating to TMO with a $510 price target, analysts believe that easing pressures from biotech and academic spending may reveal new growth drivers in the coming months, indicating potential market recovery.
See More
SNPE Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: SNPE's 52-week low is $53.72 per share, with a high of $69.64, and the latest trade at $67.86 indicates the stock is nearing its high, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed decisions.
See More
HSBC Downgrades Thermo Fisher to Hold Amid Growth Concerns
- Downgrade Impact: On June 3, HSBC downgraded Thermo Fisher from Buy to Hold and lowered its price target from $670 to $540, reflecting concerns about the company's future growth, particularly its relatively lower exposure to bioprocessing compared to peers.
- Uncertain Growth Outlook: Analysts noted that Thermo Fisher's goal of achieving 7% growth beyond 2027 requires more support, and the uncertainty surrounding outsourcing demand exacerbates market concerns about its near-term performance, potentially impacting investor confidence.
- Competitive Advantage Analysis: Despite HSBC's cautious stance, Wolfe Research initiated coverage on June 2 with an Outperform rating and a $535 price target, viewing Thermo Fisher's leadership in life science tools and its acquisition capabilities as key drivers for sustained growth.
- Investor Considerations: While Thermo Fisher is seen as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, urging investors to choose wisely.
See More
BlackRock, Thermo Fisher, and Others Declare Dividends
- BlackRock Dividend Announcement: BlackRock's Board of Directors declared a quarterly cash dividend of $5.73 per share, payable on June 23, 2026, to shareholders of record as of June 5, 2026, indicating the company's ongoing cash flow and shareholder return strategy.
- Thermo Fisher Dividend: Thermo Fisher's Board authorized a quarterly cash dividend of $0.47 per share, payable on July 15, 2026, to shareholders of record as of June 15, 2026, reflecting its robust financial performance in the science services sector.
- Franklin Resources Dividend: Franklin Resources announced a quarterly cash dividend of $0.33 per share, payable on July 10, 2026, to stockholders of record as of June 29, 2026, maintaining the same dividend as the previous quarter while representing a 3.1% increase from the same quarter last year, showcasing the company's stable profitability.
- McDonald's Dividend: McDonald's Board declared a quarterly cash dividend of $1.86 per share, payable on June 16, 2026, to shareholders of record as of June 2, 2026, demonstrating its ongoing profitability and commitment to shareholders.
See More
Arcturus Partners with Thermo Fisher to Advance Cystic Fibrosis Therapy
- Partnership Agreement: Arcturus Therapeutics has signed a partnership with Thermo Fisher Scientific to advance ARCT-032, a therapy targeting cystic fibrosis, marking a strategic move in the rare disease treatment landscape.
- Clinical Research Support: Under the agreement, Thermo Fisher will provide its PPD clinical research services to assist Arcturus in conducting a Phase 3 trial for ARCT-032, contingent on positive Phase 2 data, paving the way for future market access.
- Commercial Agreement Established: Arcturus has also entered into a commercial agreement with Thermo Fisher, granting the latter exclusive rights to ARCT-032 pending regulatory approval, enhancing the depth of collaboration in the biopharmaceutical sector.
- Clinical Trial Progress: Currently, ARCT-032 is undergoing mid-stage development, with Arcturus awaiting 12-week data from a Phase 2 open-label trial, which will significantly impact its future market potential.
See More
Danaher Corporation Rated as Top Non-Tech Stock by Analysts
- FDA 510(k) Clearance: Masimo announced FDA 510(k) clearance for its Radius VSM® wearable continuous patient monitor, which now includes an opioid-induced respiratory depression detection capability that utilizes advanced pattern recognition to analyze continuous physiological data, enabling clinicians to identify early signs of respiratory compromise in patients receiving opioid therapy, thereby enhancing patient safety and monitoring efficiency.
- Analyst Rating Changes: Piper Sandler has initiated coverage of Danaher Corporation (DHR) while expressing caution regarding its future growth catalysts, noting that the current growth outlook is similar to past performance and that Thermo Fisher appears slightly cheaper on a P/E basis, indicating market divergence in expectations for Danaher's future performance.
- Market Positioning Analysis: Danaher’s design, manufacturing, and marketing of professional, medical, industrial, and commercial products and services position it as a significant diagnostics stock, although analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, reflecting a diverse perspective on investment opportunities in the current market.
- Investment Potential Assessment: While Danaher is viewed as a potentially strong investment, analysts express insufficient confidence in its future growth, suggesting that in the current market environment, some AI stocks may be more attractive, prompting investors to carefully consider the balance of risk and reward in their selections.
See More
Thermo Fisher Named Among Top Dividend Stock Picks by Steven Cohen
- Dividend Stock Recommendation: Billionaire Steven Cohen includes Thermo Fisher Scientific (TMO) in his top 11 dividend stock picks, indicating strong recognition of the company's stable returns, which may attract more income-seeking investors.
- Analyst Coverage Resumed: Bernstein resumed coverage of TMO on June 26 with a Market Perform rating and a $520 price target, reflecting analysts' optimism about the life sciences tools and diagnostics sector, anticipating increased customer spending in the future.
- Industry Outlook Improvement: Bernstein noted improvements in new drug approvals, clinical trial initiations, and funding over the past 12 months, expecting these factors to drive customer spending growth, thereby enhancing Thermo Fisher's market performance.
- Market Competition Analysis: While Piper Sandler assigned a Neutral rating to TMO with a $510 price target, analysts believe that easing pressures from biotech and academic spending may reveal new growth drivers in the coming months, indicating potential market recovery.
See More
SNPE Stock Price Analysis and ETF Dynamics
- Price Fluctuation Analysis: SNPE's 52-week low is $53.72 per share, with a high of $69.64, and the latest trade at $67.86 indicates the stock is nearing its high, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average can provide valuable insights for investors, helping to assess price trends and identify potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding focuses on those experiencing significant inflows or outflows, allowing investors to evaluate the impact on underlying assets and make more informed decisions.
See More
HSBC Downgrades Thermo Fisher to Hold Amid Growth Concerns
- Downgrade Impact: On June 3, HSBC downgraded Thermo Fisher from Buy to Hold and lowered its price target from $670 to $540, reflecting concerns about the company's future growth, particularly its relatively lower exposure to bioprocessing compared to peers.
- Uncertain Growth Outlook: Analysts noted that Thermo Fisher's goal of achieving 7% growth beyond 2027 requires more support, and the uncertainty surrounding outsourcing demand exacerbates market concerns about its near-term performance, potentially impacting investor confidence.
- Competitive Advantage Analysis: Despite HSBC's cautious stance, Wolfe Research initiated coverage on June 2 with an Outperform rating and a $535 price target, viewing Thermo Fisher's leadership in life science tools and its acquisition capabilities as key drivers for sustained growth.
- Investor Considerations: While Thermo Fisher is seen as a potential investment, analysts suggest that certain AI stocks may offer greater upside potential and lower downside risk, urging investors to choose wisely.
See More
BlackRock, Thermo Fisher, and Others Declare Dividends
- BlackRock Dividend Announcement: BlackRock's Board of Directors declared a quarterly cash dividend of $5.73 per share, payable on June 23, 2026, to shareholders of record as of June 5, 2026, indicating the company's ongoing cash flow and shareholder return strategy.
- Thermo Fisher Dividend: Thermo Fisher's Board authorized a quarterly cash dividend of $0.47 per share, payable on July 15, 2026, to shareholders of record as of June 15, 2026, reflecting its robust financial performance in the science services sector.
- Franklin Resources Dividend: Franklin Resources announced a quarterly cash dividend of $0.33 per share, payable on July 10, 2026, to stockholders of record as of June 29, 2026, maintaining the same dividend as the previous quarter while representing a 3.1% increase from the same quarter last year, showcasing the company's stable profitability.
- McDonald's Dividend: McDonald's Board declared a quarterly cash dividend of $1.86 per share, payable on June 16, 2026, to shareholders of record as of June 2, 2026, demonstrating its ongoing profitability and commitment to shareholders.
See More
